RSS Feed ALL

Johnson & Johnson Advances Polyphonic™ AI Fund for Surgery for Data-Driven Healthcare

about 13 hours ago

First awardees selected for Polyphonic™ AI Fund for Surgery QuickFire Challenge Polyphonic...

New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile

about 13 hours ago

Findings highlight opportunity for shared decision-making to improve treatment planning, with more...

Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis

about 14 hours ago

Building on 12-week findings, icotrokinra demonstrated clinically meaningful outcomes at Week 28...

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn’s disease at two years

about 14 hours ago

Clinical remission rates were over 85% for both TREMFYA® maintenance doses at...

Published in The Lancet: Nipocalimab significantly decreased Sjögren’s disease (SjD) activity and severity through substantial reduction in Sjögren’s-related autoantibodies

3 days ago

Nipocalimab, a first-in-class FcRn blocker being investigated for SjD, met its primary...

Johnson & Johnson MedTech Highlights Newest Impella Heart Pump and Long-Term Survival Data at TCT 2025

4 days ago

The Ninth Generation Impella CP demonstrates continued innovation in improving outcomes for...

Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis

4 days ago

In areas of high impact, 72% of patients with scalp psoriasis and...

Johnson & Johnson to Participate in the 7th Annual Wolfe Research Healthcare Conference

5 days ago

Johnson & Johnson’s INLEXZO™ (gemcitabine intravesical system) plus cetrelimab delivers strong pre-surgical results in patients with muscle invasive bladder cancer scheduled for radical cystectomy

8 days ago

Phase 2b SunRISe-4 study shows 38% of patients treated with INLEXZO™-based combination...

Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

8 days ago

Responses were rapid and durable, and tumor shrinkage was observed in 82...

TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care

12 days ago

First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit...

Johnson & Johnson receives U.S. FDA Priority Review for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) in BRCA-mutated metastatic castration-sensitive prostate cancer

12 days ago